Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

704
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
704
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

13.3K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
13.3K
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

673
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
673
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

657
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
657
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

450
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
450
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

2.2K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zebrafish behavioral assessment as a first-tier whole-organism NAM for developmental neurotoxicity: A multi-laboratory evaluation.

Neurotoxicology·2026
Same author

Integrated Chemical and Toxicity Screening of Tap Drinking Water across Western Oregon Using Suspect and Nontarget Screening.

Environmental science & technology·2026
Same author

Corrigendum to "Chemical structure drives developmental toxicity of alkyl-substituted naphthalenes in zebrafish" [Environ. Int. 204 (2025) 109837].

Environment international·2026
Same author

Morphological, Behavioral, and Transcriptomic Profiling Reveals Developmental Toxicity of PCB Metabolites in Zebrafish.

Toxics·2026
Same author

FINS: An interactive platform for automated zebrafish image analysis and morphological screening.

SLAS technology·2026
Same author

Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Apr 20, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.7K

Molecular structural characteristics important in drug-HSA binding.

Snezana Agatonovic-Kustrin, David W Morton, Lisa Truong

  • 1School of Pharmacy and Applied Science, La Trobe Institute of Molecular Sciences, La Trobe University, Bendigo, Australia. s.kustrin@latrobe.edu.au.

Combinatorial Chemistry & High Throughput Screening
|November 21, 2014
PubMed
Summary

A new quantitative structure-activity relationship (QSAR) model predicts drug protein binding using molecular descriptors. This robust model aids in screening drug candidates and adjusting dosages based on predicted protein binding (PB %).

More Related Videos

Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII
08:26

Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII

Published on: August 31, 2018

7.4K
Characterization of Proteins by Size-Exclusion Chromatography Coupled to Multi-Angle Light Scattering SEC-MALS
10:00

Characterization of Proteins by Size-Exclusion Chromatography Coupled to Multi-Angle Light Scattering SEC-MALS

Published on: June 20, 2019

59.1K

Related Experiment Videos

Last Updated: Apr 20, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.7K
Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII
08:26

Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII

Published on: August 31, 2018

7.4K
Characterization of Proteins by Size-Exclusion Chromatography Coupled to Multi-Angle Light Scattering SEC-MALS
10:00

Characterization of Proteins by Size-Exclusion Chromatography Coupled to Multi-Angle Light Scattering SEC-MALS

Published on: June 20, 2019

59.1K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Drug protein binding significantly impacts pharmacokinetics and pharmacodynamics.
  • Predicting drug protein binding is crucial for drug development and dosage optimization.
  • Existing methods for determining protein binding can be resource-intensive.

Purpose of the Study:

  • To develop a non-linear quantitative structure-activity relationship (QSAR) model for predicting drug protein binding.
  • To establish a computational tool for screening drug candidates based on their protein binding potential.
  • To simplify the prediction of protein binding percentage (PB %) from molecular structure.

Main Methods:

  • Development of a non-linear QSAR model using 350 drug molecules.
  • Correlation of experimentally measured protein binding values with ten calculated molecular descriptors.
  • Application of a radial basis function (RBF) neural network for model construction.

Main Results:

  • The developed QSAR model demonstrates a statistically significant correlation (r > 0.73).
  • The model achieved a high efficiency ratio (0.986) and a good predictive squared correlation coefficient (q(2)) of 0.532.
  • The model is considered robust and of high quality, suitable for predictive applications.

Conclusions:

  • The developed RBF-based QSAR model provides a reliable method for predicting drug protein binding.
  • This model can be utilized for efficient screening of drug candidates and filtering compounds with undesirable binding profiles.
  • The model offers a valuable tool for assisting in dose adjustment for drugs with high protein binding characteristics.